In November 1997, following receipt of notification from the UK Medicines Control Agency, the Irish Medicines Board took steps, in co-operation with the distributors of the product, to ensure a full recall of relevant batches of the Amerscan Pulmonate II agent which was used in the diagnosis of abnormal lung perfusion in patients. As I have informed the House previously, the number of persons who received the withdrawn product in Irish hospitals was 460. Each of the nine hospitals involved was asked by my Department to identify all patients who were administered the product and to make arrangements to inform each person and to provide appropriate counselling.